<DOC>
	<DOCNO>NCT01157650</DOCNO>
	<brief_summary>Primary outcome measure : Evaluation viability , security tolerance adipose-derived mesenchymal stem cell implant ( ASCs ) fistulizing Crohn 's disease patient , collect reaction adverse event occur study . Secondary outcome measure : 1 . Evaluating Adipose-derived mesenchymal stem cell therapeutic effect , particular : - Fistulas heal efficiency - Changes quality life patient treat - Changes systemic Crohn 's disease implant - Relapse rate monitor among patient achieve Adipose-derived mesenchymal Stem Cells treatment success . 2 . Achieving biological characterization cell product use correlation therapeutic effect measure : - Phenotype study - Suppressor capacity study . - Citoquines production analysis</brief_summary>
	<brief_title>Treatment Fistulous Crohn 's Disease Implant Autologous Mesenchymal Stem Cells Derived From Adipose Tissue</brief_title>
	<detailed_description>The aim study evaluate role Autologous Mesechymal Stem Cells derive adipose tissue treatment fistulous Crohn disease . 15 Crohn 's disease patient one enterocutaneous , recto-vaginal complex perianal fistula , include . The trial divide three phase : I . - Selection : Patients evaluation study eligibility take place within two week Informed Consent signature . Fistulous disease evaluate MRI perianal rectovaginal fistula , CT scan case enterocutaneous fistula . Previous laboratory test radiological study valid evaluation obtain within two six month , respectively , prior evaluation , absence clinical change . II.- Treatment phase include : 1 . Liposuction procedure obtain adipose tissue . 2 . Processing production Autologous Mesenchymal Stem Cells adipose tissue ( ASCs ) 3 . ASCs implant III.- Follow : Study visit post-implant take place 1st week ( +/- 3 day ) , 4th week ( +/- 3 day ) , 8th week ( +/- 7 day ) , 12nd week ( +/- 7 day ) , 24th week ( +/- 7 day ) , 1 year ( +/- 7 day ) implant .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Fistulizing Crohn´s disease patient 1 enterocutaneous fistula , rectovaginal fistula complex perianal fistula . The complex perianal fistula define fistula present one condition : Transsphincteric , suprasphincteric extrasphincteric tract , determine : Clinical criterion : No palpation tract surgical exploration Radiological criterion : Nucleal Magnetic Resonance ( NMR ) Echoendoscopy Multiple fistulas `` Horseshoe '' fistula Any fistula fecal incontinence associate Any fistula risk fecal incontinence result : previous anal fistula surgery perianal pathology ( hemorrhoid , fissure ) , involve lesion muscular complication . Obstetric iatrogenic sphincter lesion 2 . Patients Crohn Disease ( CD ) screening diagnose within 12 month acceptance clinical , endoscopical , anatomopathological and/or radiological criterion nonactive CD . ( Crohn´s Disease Activity Index ( CDAI ) ≤ 200 ) 3 . &gt; 18 Years gender eligible . 4 . Negative pregnancy test In female fertile subject 5 . Patient must voluntary sign informed consent performance studyrelated procedure part normal medical care . 6 . Patient , investigator 's opinion , willing able comply protocol requirement 1 . Patients highly active CD , i.e. , meet follow criterion : Presence severe proctitis ( prominent friability , spontaneous bleeding , multiple erosion , deep ulcer ) dominant active luminal disease require immediate treatment , reveal rectosigmoidoscopy CDAI ≥201 2 . Presence abscess collection drain ( reveal basal radiologic study ) . 3 . Presence seton drainage , unless remove treatment begin . 4 . Rectal and/ anal stenosis reveal rectoscopy EBA . 5 . Patients need surgery perianal region reason fistulas inclusion within 26 week treatment administration . 6 . Patients receive infliximab antiTNF agent within 8 week cell treatment administration . 7 . Patients receive tacrolimus cyclosporine within 4 week cell treatment . 8 . Patients history alcohol addictive substance abuse within 6 month inclusion . 9 . Severe uncontrolled disease ( chronic renal failure , cardio , pulmonary , … ) . 10 . Any type medical psychiatric disease consider exclusion criterion , investigator 's opinion . 11 . Patients diagnosis malignant neoplasia , except basal cell epidermoid carcinoma skin previous history malignant tumour , except evidence relapse least 5 year . 12 . Subjects congenital acquire immunodeficiency . 13 . Positive serology Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) . 14 . Patient major surgery serious traumatism within 6 week enrolment . 15 . Pregnant breastfeed woman . 16 . Physical psychical impossibility follow protocol requirement 17 . Patients receive receive investigational drug within 30 day prior basal visit . 18 . Impossibility radiological exploration ( reaction contrast material , pacemaker , claustrophobia , … )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fistulizing Crohn 's disease</keyword>
	<keyword>stem cell implant</keyword>
</DOC>